Effects of Different Early Intensive Therapies on Long-term β-cell Function

Effects of Oral Hypoglycemic Agents Combined With Short-term CSII on Glycemic Control in Newly-diagnosed Type 2 Diabetic Patients

The purpose of this study is to investigate and evaluate the effects of different oral antihyperglycaemic agents combined with short-term continuous subcutaneous insulin infusion(CSII)(1.CSII alone; 2.metformin and pioglitazone combined with CSII; 3. sitagliptin combined with CSII) on long-term glycemic control and β-cell function in newly diagnosed type 2 diabetic patients.

Inclusion Criteria:

• newly diagnosed type 2 diabetes
• fasting blood glucose (FBG) level ranging from 7.0～16.7 mmol/L
• body mass index (BMI) ranging from21～35kg/m2
• Antihyperglycaemic and antihyperlipidemic medication-naive patients

Exclusion Criteria:

• having any severe acute or chronic diabetic complications
• renal dysfunction, blood creatinine≥150µmol/L
• blood aminotransferase level rising up(more than 2 times of the upper normal limit of ALT)
• • Any severe cardiac disease including congestive cardiac failure, unstable angina or myocardial infarct in 12 months
• chronic or acute pancreatic disease
• severe systematic diseases or malignant tumor
• female patients incline to be pregnant
• being treated with corticosteroid, immunosuppressing drugs or cytotoxic drugs
• poor compliance